Estimates were made for 59 countries and territories in the IDF Europe (EUR) Region. A total of 60 data sources from 39 countries were used to generate diabetes estimates among adults in the Region. Estimates for 14 countries (Austria, Denmark, Finland, France, Georgia, Greece, , Greenland, Hungary, Lithuania, Malta, Russian Federation, Turkmenistan, United Kingdom, and Uzbekistan) were based on studies conducted within the past five years.
IDF projects that diabetes prevalence (9.2%) and number of people with diabetes (61 million) in EUR Region will increase 13 % by 2045. EUR Region has the highest number of children and adolescents with type 1 diabetes (295,000) as well as the highest incidence annually with 31,000 new cases per year. The EUR Region has also the second highest average cost per person with diabetes (USD 3,086). In 2021, 189.3 billion USD was spent on diabetes, representing 19.6% of the total spent worldwide.
| At a glance | 2000 | 2011 | 2021 | 2030 | 2045 |
|---|---|---|---|---|---|
| Diabetes estimates (20-79 y) | |||||
| People with diabetes, in 1,000s | 22,373.1 | 52,770.8 | 61,425.1 | 67,000.0 | 69,000.0 |
| Age-adjusted comparative prevalence of diabetes, % | 4.9 | 6.7 | 7.0 | 8.0 | 8.7 |
| People with undiagnosed diabetes, in 1,000s | - | - | 21,935.0 | - | - |
| Proportion of people with undiagnosed diabetes, % | - | - | 35.7 | - | - |
| Impaired glucose tolerance (IGT) estimates (20-79 y) | |||||
| People with IGT, in 1,000s | - | 62,800.0 | 54,780.2 | 56,100.0 | 55,300.0 |
| Age-adjusted comparative prevalence of IGT, % | - | 8.6 | 7.1 | 7.6 | 7.8 |
| Impaired fasting glucose (IFG) estimates (20-79 y) | |||||
| People with IFG, in 1,000s | - | - | 25,608.0 | 26,800.0 | 26,700.0 |
| Age-adjusted comparative prevalence of IFG, % | - | - | 3.3 | 3.5 | 3.7 |
| Mortality attributable to diabetes (20-79 y) | |||||
| Deaths attributable to diabetes | - | 600,000.0 | 1,111,201.0 | 0.0 | - |
| Proportion of diabetes-related deaths in people under 60 y, % | - | - | - | - | - |
| Type 1 diabetes estimates in children and adolescents | |||||
| New cases of type 1 diabetes (0-14 y), in 1,000s | 13.5 | 17.9 | 24.7 | - | - |
| New cases of type 1 diabetes (0-19 y), in 1,000s | - | - | 31.0 | - | - |
| Type 1 diabetes (0-14 y), in 1,000s | 76.8 | 116.1 | 162.6 | - | - |
| Type 1 diabetes (0-19 y), in 1,000s | - | - | 294.9 | - | - |
| Hyperglycaemia in pregnancy (HIP) (20-49 y) | |||||
| Live births affected by HIP | - | - | 1,556,371.8 | - | - |
| Prevalence of gestational diabetes mellitus (GDM), % | - | - | 15.0 | - | - |
| Live births affected by other types of diabetes first detected in pregnancy | - | - | 73,893.7 | - | - |
| Live births affected by other types of diabetes detected prior to pregnancy | - | - | 118,091.5 | - | - |
| Diabetes-related health expenditure | |||||
| Total diabetes-related health expenditure, USD million | - | 130,600.0 | 189,343.9 | 189,616.0 | 185,318.1 |
| Total diabetes-related health expenditure, ID million | - | - | 264,820.3 | 309,829.5 | 312,125.5 |
| Diabetes-related health expenditure per person, USD | - | 1,290.4 | 3,086.4 | 5,505.0 | 5,633.0 |
| Diabetes-related health expenditure per person, ID | - | - | 4,316.7 | 11,112.1 | 11,780.5 |
| Demographics | |||||
| Total adult population (20-79 y), in 1,000s | 460,837.0 | 653,000.0 | 670,341.8 | 677,000.0 | 668,000.0 |
| Population of children (0-14 y), in 1,000s | 140,719.6 | - | 169,339.0 | - | - |
| Population of children and adolescents (0-19 y), in 1,000s | - | - | 221,820.0 | - | - |